Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials
"With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." According to Eli Lilly, adults in the Phase 3 trials all lost weight with orforglipron and on the highest dose of 36 mg of orforglipron, the trial participants lost about 27 pounds over the course of 72 weeks or about 12% of their body weight, which is meaningful but not quite as high as some injectables
Works through metabolic enhancement, not hunger reduction
Potere Health MD does not manufacture compounded medications. Compounded formulations are not FDA-approved, have not been evaluated for safety or efficacy, and are not generic equivalents to commercial products
A Certificate of Analysis (COA) confirms the peptides identity and purity
Figure 14: Diagram showing the contrasting functions of glucagon and insulin, credit: Carogonz11, Wikimedia
